New clinical data in psoriasis management
A new study conducted by Italian researchers at the Department of Surgery and Translational Medicine, University of Florence, demonstrates that supplementation with Meriva, the Indena proprietary lecithin-based delivery system for curcumin, may be effective as a complementary support in skin disorders management.
In this single-dose, randomised, double-blind, placebo-controlled study 63 subjects with mild-to-moderate psoriasis vulgaris (PASI <10) were randomly divided into two groups treated with topical steroids and orally with Meriva, or with topical steroids alone, both for 12 weeks.
Researchers measured the quality of life and health benefits and the effects of the treatment on the serum levels of IL-17 and IL-22 that are thought to play a major role in this disorder.
Data from the study demonstrated that Meriva may be regarded as a safe and well-tolerated supplementation for the complementary support to subjects treated with topical steroids. Among the several biological effects of curcumin, the ability to downregulate the T cell-mediated process, and in particular the Th22 pathway, may be considered to be one of the major mechanisms by which Meriva supports skin dysfunction recovery.
Antonella Riva, Senior Scientific Researcher at Indena, commented: 'We welcome the promising results of Meriva in this new area, and the chance to improve the quality of life for people affected by this troublesome condition.'